Ann: Neuren announces cancer xenograft testing re, page-50

re: Ann: Neuren announces cancer xenograft te... "The thing to remember is that the enemy of all small Biotech companies is time and money."

That's another reason why the neu sp should be a lot higher. We have plenty of cash and we spend very little, as third parties are funding our two phase two trials. One can safely predict that the Retts trial will also be funded by others, as there is currently lots of support from cash up entities.

I would suggest that the Perseis cancer work doesn't cost that much atm. Possibly our 'partner' in Maryland will help foot the bill too???

ps. I am excited about Perseis, and I'm pleased we have it. It could become a very valuable product indeed. I just thought it was silly that the sp dropped from 3c to 2.4c as there is 17c of value elsewhere within the company. That's what I was trying to communicate in my "My thought" thread.

cheers